Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy

作者: Stephan Braun , Volkmar Müller , Klaus Pantel

DOI: 10.1007/0-306-48355-6_3

关键词: Internal medicineMinimal residual diseaseOncologyMedicineAdjuvant therapyBreast cancerOccultCA15-3CancerBone marrowAdjuvant

摘要: The early and clinically occult spread of viable tumour cells to the organism is becoming acknowledged as a hallmark in cancer progression, since abundant clinical experimental data suggest that these are precursors subsequent distant relapse. Prospective studies have shown presence such immunostained bone marrow prognostically relevant with regard relapse-free overall survival breast patients. As current treatment strategies not resulted substantial improvement mortality rates so far, it noteworthy consider intriguing options immunocytochemical screening aspirates for metastatic cells. Besides improved staging, offers opportunities guiding patient stratification adjuvant therapy trials, monitoring response therapies, which, at present, can only be assessed retrospectively after an extended period follow-up, or specifically targeting tumour-biological therapies against disseminated

参考文章(102)
Brammar Wj, Walker Ra, Varley Jm, Whittaker Jl, Swallow Je, Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. ,vol. 1, pp. 423- 430 ,(1987)
S Noguchi, Tomohiko Aihara, K Motomura, Hideo Inaji, Shingi Imaoka, Hiroki Koyama, None, Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. American Journal of Pathology. ,vol. 148, pp. 649- 656 ,(1996)
G Y Wong, M P Osborne, R K Tiwari, C Cordon-Cardo, P I Borgen, HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Research. ,vol. 12, pp. 419- 425 ,(1992)
John T. Flannery, John D. Boice, Rochelle E. Curtis, William C. Moloney, Lynn Gloeckler Ries, Leukemia following Chemotherapy for Breast Cancer Cancer Research. ,vol. 50, pp. 2741- 2746 ,(1990)
Y H Datta, P T Adams, W R Drobyski, S P Ethier, V H Terry, M S Roth, Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction Journal of Clinical Oncology. ,vol. 12, pp. 475- 482 ,(1994) , 10.1200/JCO.1994.12.3.475
Gert Riethmüller, Christina R. M. Kentenich, Wolfgang Janni, Florian Hepp, Klaus Pantel, Harald L. Sommer, Fritz Willgeroth, Stephan Braun, Monoclonal Antibody Therapy with Edrecolomab in Breast Cancer Patients: Monitoring of Elimination of Disseminated Cytokeratin-positive Tumor Cells in Bone Marrow Clinical Cancer Research. ,vol. 5, pp. 3999- 4004 ,(1999)
Ferenc Gyorkey, Harris Busch, Rose K. Busch, Brenda E. Ross, James W. Freeman, Phyllis Gyorkey, Identification and Characterization of a Human Proliferation-associated Nucleolar Antigen with a Molecular Weight of 120,000 Expressed in Early G1 Phase Cancer Research. ,vol. 48, pp. 1244- 1251 ,(1988)
Bernd Gerber, Annette Krause, Heiner Müller, Dagmar Richter, Toralf Reimer, Josef Makovitzky, Christina Herrnring, Udo Jeschke, Günther Kundt, Klaus Friese, Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors Journal of Clinical Oncology. ,vol. 19, pp. 960- 971 ,(2001) , 10.1200/JCO.2001.19.4.960